| The cost of drug development: a systematic review S Morgan, P Grootendorst, J Lexchin, C Cunningham, D Greyson Health policy 100 (1), 4-17, 2011 | 696 | 2011 |
| Prescription drug use during pregnancy in developed countries: a systematic review JR Daw, GE Hanley, DL Greyson, SG Morgan Pharmacoepidemiology and drug safety 20 (9), 895-902, 2011 | 332 | 2011 |
| The effect of cost on adherence to prescription medications in Canada MR Law, L Cheng, IA Dhalla, D Heard, SG Morgan Cmaj 184 (3), 297-302, 2012 | 300 | 2012 |
| Apocalypse no: population aging and the future of health care systems RG Evans, KM McGrail, SG Morgan, ML Barer, C Hertzman Canadian Journal on Aging/La Revue canadienne du vieillissement 20 (S1), 160-191, 2001 | 263 | 2001 |
| Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization PA Caetano, JMC Lam, SG Morgan Clinical therapeutics 28 (9), 1411-1424, 2006 | 228 | 2006 |
| “Breakthrough” drugs and growth in expenditure on prescription drugs in Canada SG Morgan, KL Bassett, JM Wright, RG Evans, ML Barer, PA Caetano, ... Bmj 331 (7520), 815-816, 2005 | 174 | 2005 |
| Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom SG Morgan, M McMahon, C Mitton, E Roughead, R Kirk, P Kanavos, ... Health Affairs 25 (2), 337-347, 2006 | 158 | 2006 |
| Frequency and cost of potentially inappropriate prescribing for older adults: a cross-sectional study SG Morgan, J Hunt, J Rioux, J Proulx, D Weymann, C Tannenbaum Canadian Medical Association Open Access Journal 4 (2), E346-E351, 2016 | 146 | 2016 |
| Stitching the gaps in the Canadian public drug coverage patchwork? A review of provincial pharmacare policy changes from 2000 to 2010 JR Daw, SG Morgan Health Policy 104 (1), 19-26, 2012 | 139 | 2012 |
| Pricing of pharmaceuticals is becoming a major challenge for health systems SG Morgan, HS Bathula, S Moon Bmj 368, 2020 | 133 | 2020 |
| Prescription drug use in pregnancy: a retrospective, population-based study in British Columbia, Canada (2001–2006) JR Daw, B Mintzes, MR Law, GE Hanley, SG Morgan Clinical therapeutics 34 (1), 239-249. e2, 2012 | 133 | 2012 |
| Patterns in the use of benzodiazepines in British Columbia: examining the impact of increasing research and guideline cautions against long-term use CM Cunningham, GE Hanley, S Morgan Health policy 97 (2-3), 122-129, 2010 | 131 | 2010 |
| Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries SG Morgan, A Lee BMJ open 7 (1), e014287, 2017 | 126 | 2017 |
| The Canadian Rx Atlas S Morgan, K Smolina, D Mooney, C Raymond, ML Bowen, C Gorczynski, ... Centre for Health Services and Policy Research (CHSPR), 2013 | 121 | 2013 |
| On the validity of area-based income measures to proxy household income GE Hanley, S Morgan BMC health services research 8, 1-7, 2008 | 121 | 2008 |
| Estimated cost of universal public coverage of prescription drugs in Canada SG Morgan, M Law, JR Daw, L Abraham, D Martin CMAJ 187 (7), 491-497, 2015 | 116 | 2015 |
| The common drug review: a NICE start for Canada? M McMahon, S Morgan, C Mitton Health Policy 77 (3), 339-351, 2006 | 108 | 2006 |
| Payers’ experiences with confidential pharmaceutical price discounts: a survey of public and statutory health systems in North America, Europe, and Australasia SG Morgan, S Vogler, AK Wagner Health Policy 121 (4), 354-362, 2017 | 100 | 2017 |
| The consequences of patient charges for prescription drugs in Canada: a cross-sectional survey MR Law, L Cheng, A Kolhatkar, LJ Goldsmith, SG Morgan, AM Holbrook, ... Canadian Medical Association Open Access Journal 6 (1), E63-E70, 2018 | 99 | 2018 |
| A cross-national study of prescription nonadherence due to cost: data from the joint Canada-United States survey of health J Kennedy, S Morgan Clinical therapeutics 28 (8), 1217-1224, 2006 | 92 | 2006 |
Kate SmolinaScientific Director, Data, Analytics & KT, BCCDC在 bccdc.ca 的电子邮件经过验证
